Published :
Tables : 49
Figures : 44
Category : Healthcare
No. of Pages : 233
Report Code : HC-U3346
Tissue Diagnostics Market is poised to value USD 7781.80 million by 2028 end at a CAGR of 6.6% during the forecast period 2022 to 2028. Tissue diagnostics is used for understanding tumors at a biological level which is why it is generally used for diagnosing cancer. There has been a surging demand for tissue diagnostics with a rising prevalence of cancer across the world, thereby contributing to the growth of the market. As per the data provided by the Globocan, over 14 million newly registered cancer cases and over 8 million deaths related to cancer were recorded in 2012 and it is estimated that this numbers shall reach over 17 million and over 10 million by 2021. Based on this data, the EHO and the ICRA predicted that over 19 million new cancer cases will be recorded by 2025 and this hike in the number of patients is primarily due to the increasing geriatric population. AS pe the WHO report, the geriatric population is expected to rise from over 11% in 2015 to over 21% by 2050, which shall increase the cancer patient pool, thereby proliferating the market. Research institutes are working on automizing the tissue-based diagnosis which shall help in obtaining a faster tumor diagnosis. Furthermore, there has been a surging demand for customised medical care and with some extensive ongoing research, it will be possible to produce companion tissue diagnostic kits which is likely to positively impact the market growth. In case of the share distribution amongst market players, over 80 percent of the total market is held by five major players and due to these players have established a high level of brand loyalty which makes it difficult for emerging players to enter the market and establish their position as theses players are not at the same financial level as the established players are in terms of research infrastructure and workforce. Such factors can negatively impact the market growth during the forecast period. There has been a significant change in the pathology sector with many clinicians shifting from traditional pathology to digital pathology, thereby allowing them to reduce the test turnaround time, enhance the outcome of patients and prioritise critical cases. For example, Alverno Laboratories in May 2019, partnered with the Royal Philips, introduced the IntelliSite Pathology Solution of Philips in their clinical labs for enhancing lab quality, patient safety and efficiency. This shall significantly boost the tissue diagnostics market growth. Market Segmentation: By Product • Consumables o Antibodies o Reagents o Kits o Probes • Instruments o Slide Staining Systems o Scanners o Tissue Processing Systems o Other Instruments By Technology • In-Situ Hybridization • Immunohistochemistry • Special Staining • Digital Pathology and Workflow By Disease • Breast Cancer • Gastric Cancer • Lymphoma • Prostate Cancer • Non-Small Cell Lung Cancer • Others By End User • Hospitals • Pharmaceutical Companies • Research Laboratories • Contract Research Organizations • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa The market is classified into product, technology, disease, end user and region. The product segment is categorised into consumables and instruments. The consumables segment is predicted to hold the largest tissue diagnostics market share, and this can be attributed to an increased usage of consumables for tissue diagnostics and technological advancements in consumables for increasing their efficiency. The technology segment is fragmented into in situ hybridization, special staining, digital pathology and workflow and immunohistochemistry. The immunohistochemistry segment is anticipated to dominate the market during the forecasted timeframe. It is been widely used in the clinical R&D of cancer therapeutics and diagnostics. Furthermore, it is mainly preferred over traditional enzyme staining methods as it is capable of providing specific tumor variations whereas the traditional techniques can only detect a limited number of protein tumors, enzymes and tissue structures. The disease segment is categorised into breast cancer, gastric cancer, lymphoma, prostrate cancer, non-small cell lung cancer and others. The breast cancer segment is predicted to lead the market owing to an increased incidence of breast cancer worldwide. This has mainly been due to unawareness regarding the development of breast cancer and unhealthy and a stressful lifestyle leading to the formation of such cancerous tumors. The end user segment is divided into hospitals, pharmaceutical companies, research laboratories, contract research organizations and others. The contract research organization segment is estimated to experience substantial growth owing to their capability of providing and managing clinical trial services, bolster research activities and aid companies facing budget constraints. Regional Analysis: The North America region is predicted to lead the market during the forecast period. The CDC program of Cancer Prevention and Control Research Network focusses on the steps to be taken to prevent cancer. Furthermore, there has been a rising demand for personalised medicinal methods to be implemented in the healthcare sector with a rise in the healthcare IT systems, thereby easing the adoption of sequencing methods in the region. The Asia Pacific region is predicted to grow at a substantial rate during the forecast period and this can be credited to the increased adoption of tissue diagnostic methods in the region. For example, HalioDx SAS and Genecast signed an agreement in April 2019 for commercializing the Immunoscore diagnostic assay of HalioDx in China. Competitive Landscape: The prominent market players included are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Siemens, Danaher, bioMérieux SA, QIAGEN, Becton Dickinson and Company, Merck KGaA, GE Healthcare, BioGenex, Cell Signaling Technology Inc., Bio SB, DiaGenic ASA, Agilent Technologies. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global tissue diagnostics market by product, by technology, by disease, by end user and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Tissue diagnostics is used for understanding tumors at a biological level which is why it is generally used for diagnosing cancer. There has been a surging demand for tissue diagnostics with a rising prevalence of cancer across the world, thereby contributing to the growth of the market. As per the data provided by the Globocan, over 14 million newly registered cancer cases and over 8 million deaths related to cancer were recorded in 2012 and it is estimated that this numbers shall reach over 17 million and over 10 million by 2021. Based on this data, the EHO and the ICRA predicted that over 19 million new cancer cases will be recorded by 2025 and this hike in the number of patients is primarily due to the increasing geriatric population. AS pe the WHO report, the geriatric population is expected to rise from over 11% in 2015 to over 21% by 2050, which shall increase the cancer patient pool, thereby proliferating the market.
Research institutes are working on automizing the tissue-based diagnosis which shall help in obtaining a faster tumor diagnosis. Furthermore, there has been a surging demand for customised medical care and with some extensive ongoing research, it will be possible to produce companion tissue diagnostic kits which is likely to positively impact the market growth. In case of the share distribution amongst market players, over 80 percent of the total market is held by five major players and due to these players have established a high level of brand loyalty which makes it difficult for emerging players to enter the market and establish their position as theses players are not at the same financial level as the established players are in terms of research infrastructure and workforce. Such factors can negatively impact the market growth during the forecast period.
There has been a significant change in the pathology sector with many clinicians shifting from traditional pathology to digital pathology, thereby allowing them to reduce the test turnaround time, enhance the outcome of patients and prioritise critical cases. For example, Alverno Laboratories in May 2019, partnered with the Royal Philips, introduced the IntelliSite Pathology Solution of Philips in their clinical labs for enhancing lab quality, patient safety and efficiency. This shall significantly boost the tissue diagnostics market growth.
Market Segmentation:
By Product • Consumables o Antibodies o Reagents o Kits o Probes • Instruments o Slide Staining Systems o Scanners o Tissue Processing Systems o Other Instruments By Technology • In-Situ Hybridization • Immunohistochemistry • Special Staining • Digital Pathology and Workflow By Disease • Breast Cancer • Gastric Cancer • Lymphoma • Prostate Cancer • Non-Small Cell Lung Cancer • Others By End User • Hospitals • Pharmaceutical Companies • Research Laboratories • Contract Research Organizations • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
The market is classified into product, technology, disease, end user and region. The product segment is categorised into consumables and instruments. The consumables segment is predicted to hold the largest tissue diagnostics market share, and this can be attributed to an increased usage of consumables for tissue diagnostics and technological advancements in consumables for increasing their efficiency. The technology segment is fragmented into in situ hybridization, special staining, digital pathology and workflow and immunohistochemistry. The immunohistochemistry segment is anticipated to dominate the market during the forecasted timeframe. It is been widely used in the clinical R&D of cancer therapeutics and diagnostics. Furthermore, it is mainly preferred over traditional enzyme staining methods as it is capable of providing specific tumor variations whereas the traditional techniques can only detect a limited number of protein tumors, enzymes and tissue structures. The disease segment is categorised into breast cancer, gastric cancer, lymphoma, prostrate cancer, non-small cell lung cancer and others. The breast cancer segment is predicted to lead the market owing to an increased incidence of breast cancer worldwide. This has mainly been due to unawareness regarding the development of breast cancer and unhealthy and a stressful lifestyle leading to the formation of such cancerous tumors. The end user segment is divided into hospitals, pharmaceutical companies, research laboratories, contract research organizations and others. The contract research organization segment is estimated to experience substantial growth owing to their capability of providing and managing clinical trial services, bolster research activities and aid companies facing budget constraints.
Regional Analysis:
The North America region is predicted to lead the market during the forecast period. The CDC program of Cancer Prevention and Control Research Network focusses on the steps to be taken to prevent cancer. Furthermore, there has been a rising demand for personalised medicinal methods to be implemented in the healthcare sector with a rise in the healthcare IT systems, thereby easing the adoption of sequencing methods in the region. The Asia Pacific region is predicted to grow at a substantial rate during the forecast period and this can be credited to the increased adoption of tissue diagnostic methods in the region. For example, HalioDx SAS and Genecast signed an agreement in April 2019 for commercializing the Immunoscore diagnostic assay of HalioDx in China.
Competitive Landscape:
The prominent market players included are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Siemens, Danaher, bioMérieux SA, QIAGEN, Becton Dickinson and Company, Merck KGaA, GE Healthcare, BioGenex, Cell Signaling Technology Inc., Bio SB, DiaGenic ASA, Agilent Technologies.
FutureWise Key Takeaways:
• Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global tissue diagnostics market by product, by technology, by disease, by end user and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Tissue Diagnostics Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Tissue Diagnostics Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Tissue Diagnostics Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Tissue Diagnostics Market, By Product Historical Analysis and Forecast 2022-2028 (USD million) 7.1 Consumables 7.1.1 Antibodies 7.1.2 Reagents 7.1.3 Kits 7.1.4 Probes 7.2 Instruments 7.2.1 Slide Staining Systems 7.2.2 Scanners 7.2.3 Tissue Processing Systems 7.2.4 Other Instruments 8. Tissue Diagnostics Market, By Technology Historical Analysis and Forecast 2022-2028 (USD million) 8.1 In-Situ Hybridization 8.2 Immunohistochemistry 8.3 Special Staining 8.4 Digital Pathology and Workflow 9. Tissue Diagnostics Market, By Disease Historical Analysis and Forecast 2022-2028 (USD million) 9.1 Breast Cancer 9.2 Gastric Cancer 9.3 Lymphoma 9.4 Prostate Cancer 9.5 Non-Small Cell Lung Cancer 9.6 Others 10. Tissue Diagnostics Market, By End User Historical Analysis and Forecast 2022-2028 (USD million) 10.1 Hospitals 10.2 Pharmaceutical Companies 10.3 Research Laboratories 10.4 Contract Research Organizations 10.5 Others 11. North America Tissue Diagnostics Market Analysis 2016-2022 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2022 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028 12. Latin America Tissue Diagnostics Market Analysis 2016-2022 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2022 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028 13. Europe Tissue Diagnostics Market Analysis 2016-2022 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2022 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028 14. Asia Pacific Tissue Diagnostics Market Analysis 2016-2022 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2022 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 15. Middle East and Africa Market Analysis 2016-2022 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2022 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028 16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 17.1. F. Hoffmann-La Roche Ltd. 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Abbott Laboratories 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Thermo Fisher Scientific Inc. 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. Siemens 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Danaher 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. bioMérieux SA 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. QIAGEN 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Becton Dickinson and Company 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Merck KGaA 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10.GE Healthcare 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11.BioGenex 17.11.1. Company Overview 17.11.2. Product Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12.Cell Signaling Technology Inc. 17.12.1. Company Overview 17.12.2. Product Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13.Bio SB 17.13.1. Company Overview 17.13.2. Product Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview 17.14.PfDiaGenic ASAizer 17.14.1. Company Overview 17.14.2. Product Portfolio 17.14.3. SWOT Analysis 17.14.4. Financial Overview 17.14.5. Strategic Overview 17.15.Agilent Technologies 17.15.1. Company Overview 17.15.2. Product Portfolio 17.15.3. SWOT Analysis 17.15.4. Financial Overview 17.15.5. Strategic Overview 17.16.Emerging Companies. 17.16.1. Company Overview 17.16.2. Product Portfolio 17.16.3. SWOT Analysis 17.16.4. Financial Overview 17.16.5. Strategic Overview 18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Tissue Diagnostics Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Tissue Diagnostics Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Tissue Diagnostics Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Tissue Diagnostics Market, By Product Historical Analysis and Forecast 2022-2028 (USD million) 7.1 Consumables 7.1.1 Antibodies 7.1.2 Reagents 7.1.3 Kits 7.1.4 Probes 7.2 Instruments 7.2.1 Slide Staining Systems 7.2.2 Scanners 7.2.3 Tissue Processing Systems 7.2.4 Other Instruments 8. Tissue Diagnostics Market, By Technology Historical Analysis and Forecast 2022-2028 (USD million) 8.1 In-Situ Hybridization 8.2 Immunohistochemistry 8.3 Special Staining 8.4 Digital Pathology and Workflow 9. Tissue Diagnostics Market, By Disease Historical Analysis and Forecast 2022-2028 (USD million) 9.1 Breast Cancer 9.2 Gastric Cancer 9.3 Lymphoma 9.4 Prostate Cancer 9.5 Non-Small Cell Lung Cancer 9.6 Others 10. Tissue Diagnostics Market, By End User Historical Analysis and Forecast 2022-2028 (USD million) 10.1 Hospitals 10.2 Pharmaceutical Companies 10.3 Research Laboratories 10.4 Contract Research Organizations 10.5 Others
11. North America Tissue Diagnostics Market Analysis 2016-2022 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2022 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028
12. Latin America Tissue Diagnostics Market Analysis 2016-2022 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2022 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028
13. Europe Tissue Diagnostics Market Analysis 2016-2022 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2022 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028
14. Asia Pacific Tissue Diagnostics Market Analysis 2016-2022 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2022 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
15. Middle East and Africa Market Analysis 2016-2022 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2022 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028
16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix
17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 17.1. F. Hoffmann-La Roche Ltd. 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Abbott Laboratories 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Thermo Fisher Scientific Inc. 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. Siemens 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Danaher 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. bioMérieux SA 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. QIAGEN 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Becton Dickinson and Company 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Merck KGaA 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10.GE Healthcare 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11.BioGenex 17.11.1. Company Overview 17.11.2. Product Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12.Cell Signaling Technology Inc. 17.12.1. Company Overview 17.12.2. Product Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13.Bio SB 17.13.1. Company Overview 17.13.2. Product Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview 17.14.PfDiaGenic ASAizer 17.14.1. Company Overview 17.14.2. Product Portfolio 17.14.3. SWOT Analysis 17.14.4. Financial Overview 17.14.5. Strategic Overview 17.15.Agilent Technologies 17.15.1. Company Overview 17.15.2. Product Portfolio 17.15.3. SWOT Analysis 17.15.4. Financial Overview 17.15.5. Strategic Overview 17.16.Emerging Companies. 17.16.1. Company Overview 17.16.2. Product Portfolio 17.16.3. SWOT Analysis 17.16.4. Financial Overview 17.16.5. Strategic Overview
18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations
19. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics